Brian Druker

Druker is married to Alexandra Hardy, a one-time reporter for People magazine, and the couple have three children.

Druker is married to Alexandra Hardy, a one-time reporter for People magazine, and the couple have three children

Druker is married to Alexandra Hardy, a one-time reporter for People magazine, and the couple have three children (as of 2009). An earlier marriage, to Barbara Rodriguez in 1990, ended in divorce in 1999.

Druker is married to Alexandra Hardy, a one-time reporter for People magazine, and the couple have three children (as of 2009).[4] An earlier marriage, to Barbara Rodriguez in 1990, ended in divorce in 1999.

Druker is married to Alexandra Hardy, a one-time reporter for People magazine, and the couple have three children (as of 2009).[4] An earlier marriage, to Barbara Rodriguez in 1990, ended in divorce in 1999.

Druker is married to Alexandra Hardy, a one-time reporter for People magazine, and the couple have three children (as of 2009).[4] An earlier marriage, to Barbara Rodriguez in 1990, ended in divorce in 1999

Druker has been widely recognized for his work in developing the cancer-fighting drug commonly known as Gleevec, but has been publicly critical of the drug's high price for patients.

Druker has been widely recognized for his work in developing the cancer-fighting drug commonly known as Gleevec,[7] but has been publicly critical of the drug's high price for patients.

Druker has been widely recognized for his work in developing the cancer-fighting drug commonly known as Gleevec,[7] but has been publicly critical of the drug's high price for patients.[9]

Druker has been widely recognized for his work in developing the cancer-fighting drug commonly known as Gleevec,[7] but has been publicly critical of the drug's high price for patients.[9]

In 2009,In 2009, he won the Lasker-DeBakey Clinical Medical Research Award and the Meyenburg Award for his influential work in the development of Imatinib, commonly known as Gleevec, for the treatment of chronic myeloid leukemia.

Is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine.

Is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine. In 2009, he won the Lasker-DeBakey Clinical Medical Research Award and the Meyenburg Award for his influential work in the development of Imatinib, commonly known as Gleevec, for the treatment of chronic myeloid leukemia.

Is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine. In 2009, he won the Lasker-DeBakey Clinical Medical Research Award[3][4] and the Meyenburg Award for his influential work in the development of Imatinib, commonly known as Gleevec, for the treatment of chronic myeloid leukemia.

Is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine. In 2009, he won the Lasker-DeBakey Clinical Medical Research Award[3][4] and the Meyenburg Award[1] for his influential work in the development of Imatinib, commonly known as Gleevec, for the treatment of chronic myeloid leukemia.

Is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine. In 2009, he won the Lasker-DeBakey Clinical Medical Research Award[3][4] and the Meyenburg Award[1] for his influential work in the development of Imatinib (or STI571), commonly known as Gleevec, for the treatment of chronic myeloid leukemia.

Is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine. In 2009, he won the Lasker-DeBakey Clinical Medical Research Award[3][4] and the Meyenburg Award[1] for his influential work in the development of Imatinib (or STI571), commonly known as Gleevec, for the treatment of chronic myeloid leukemia (CML).

Is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine. In 2009, he won the Lasker-DeBakey Clinical Medical Research Award[3][4] and the Meyenburg Award[1] for his influential work in the development of Imatinib (or STI571), commonly known as Gleevec, for the treatment of chronic myeloid leukemia (CML).He has been called "Oregon's best-known scientist".

He has been called "Oregon's best-known scientist".

Is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine. In 2009, he won the Lasker-DeBakey Clinical Medical Research Award[3][4] and the Meyenburg Award[1] for his influential work in the development of Imatinib (or STI571), commonly known as Gleevec, for the treatment of chronic myeloid leukemia (CML).[1] He.He has been called "Oregon's best-known scientist".